CTLA4 and acute kidney injury: Additionally, PD-1 inhibitors such as dostarlimab (ROR 29.43; IC0.25: 2.97), and CTLA-4 inhibitors such as tremelimumab (ROR 23.78; IC0.25: 2.81) showed significant associations with AKI.